PPARA and metabolic dysfunction-associated steatohepatitis: Recently, a PPAR-α/γ dual agonist (Saroglitazar) exhibited promising data (improved liver injury, insulin resistance, and atherogenic dyslipidaemia) in Phase 2 trial (NCT03061721) in patients with NAFLD/NASH, with the hope to progress to phase 3.224